从美国住院患者中分离出的病原体的抗菌药敏性以及新型甘氨酰环素类抗菌药物替加环素的体外活性。
Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
作者信息
Waites Ken B, Duffy Lynn B, Dowzicky Michael J
机构信息
Section of Clinical Microbiology, University of Alabama at Birmingham, Birmingham, AL 35249, USA.
出版信息
Antimicrob Agents Chemother. 2006 Oct;50(10):3479-84. doi: 10.1128/AAC.00210-06.
Abstract
The activities of tigecycline and comparators against isolates collected from 76 U.S. centers between January 2004 and September 2005 were assessed. Tigecycline MIC(90)s were < or =2 microg/ml for Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens, Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Streptococcus agalactiae.
摘要
对2004年1月至2005年9月间从美国76个中心收集的分离菌株进行了替加环素及对照药物活性评估。肺炎克雷伯菌、产酸克雷伯菌、大肠埃希菌、产气肠杆菌、阴沟肠杆菌、粘质沙雷菌、鲍曼不动杆菌、金黄色葡萄球菌、粪肠球菌、屎肠球菌和无乳链球菌的替加环素MIC（90）≤2μg/ml。
相似文献
1
Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
Antimicrob Agents Chemother. 2006 Oct;50(10):3479-84. doi: 10.1128/AAC.00210-06.
2
Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Clin Ther. 2008 Nov;30(11):2040-50. doi: 10.1016/j.clinthera.2008.11.006.
3
In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
Diagn Microbiol Infect Dis. 2009 Nov;65(3):288-99. doi: 10.1016/j.diagmicrobio.2009.07.010. Epub 2009 Sep 4.
4
In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
Int J Antimicrob Agents. 2014 Feb;43(2):170-8. doi: 10.1016/j.ijantimicag.2013.10.011. Epub 2013 Nov 15.
5
Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Ann Clin Microbiol Antimicrob. 2017 Jul 12;16(1):50. doi: 10.1186/s12941-017-0222-0.
6
Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Diagn Microbiol Infect Dis. 2005 Jul;52(3):187-93. doi: 10.1016/j.diagmicrobio.2005.05.004.
7
Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
Ann Clin Microbiol Antimicrob. 2015 Dec 15;14:53. doi: 10.1186/s12941-015-0116-y.
8
Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
Int J Antimicrob Agents. 2013 Jun;41(6):527-35. doi: 10.1016/j.ijantimicag.2013.02.022. Epub 2013 Apr 13.
9
Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Int J Antimicrob Agents. 2009 Aug;34(2):121-30. doi: 10.1016/j.ijantimicag.2009.02.003. Epub 2009 Apr 1.
10
Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Antimicrob Resist Infect Control. 2018 Dec 13;7:152. doi: 10.1186/s13756-018-0441-y. eCollection 2018.
引用本文的文献
1
Analysis of Efflux Pump System and Other Drug Resistance Related Gene Mutations in Tigecycline-Resistant .
Comput Math Methods Med. 2023 Feb 17;2023:8611542. doi: 10.1155/2023/8611542. eCollection 2023.
2
The Pharmacokinetics/Pharmacodynamics and Neurotoxicity of Tigecycline Intraventricular Injection for the Treatment of Extensively Drug-Resistant Intracranial Infection.
Infect Drug Resist. 2022 Aug 24;15:4809-4817. doi: 10.2147/IDR.S377772. eCollection 2022.
3
Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.
Biomed Res Int. 2016;2016:8395268. doi: 10.1155/2016/8395268. Epub 2016 Dec 4.
4
Determination of susceptibility to fosfomycin and tigecycline of Enterobacteriaceae, particularly Escherichia coli isolates, producing extended-spectrum β-lactamases from multiple regional Canadian hospitals.
Can J Infect Dis Med Microbiol. 2013 Fall;24(3):e80-2. doi: 10.1155/2013/645018.
5
Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia.
Infect Drug Resist. 2011;4:77-86. doi: 10.2147/IDR.S6030. Epub 2011 Mar 2.
6
Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges.
Antimicrob Agents Chemother. 2011 Jan;55(1):449-50. doi: 10.1128/AAC.00635-10. Epub 2010 Oct 11.
7
Multidrug-resistant Gram-negative infections: what are the treatment options?
Drugs. 2009 Oct 1;69(14):1879-901. doi: 10.2165/11315690-000000000-00000.
8
Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
Antimicrob Agents Chemother. 2009 Mar;53(3):1165-9. doi: 10.1128/AAC.00647-08. Epub 2008 Dec 29.
9
Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany.
Eur J Clin Microbiol Infect Dis. 2009 Jan;28(1):83-90. doi: 10.1007/s10096-008-0589-0. Epub 2008 Aug 21.
10
Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.
J Antimicrob Chemother. 2008 Nov;62(5):895-904. doi: 10.1093/jac/dkn311. Epub 2008 Aug 1.
本文引用的文献
1
Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004).
J Chemother. 2005 Oct;17(5):459-69. doi: 10.1179/joc.2005.17.5.459.
2
Clinical impact and pathogenicity of Acinetobacter.
Clin Microbiol Infect. 2005 Nov;11(11):868-73. doi: 10.1111/j.1469-0691.2005.01227.x.
3
Overview of nosocomial infections caused by gram-negative bacilli.
Clin Infect Dis. 2005 Sep 15;41(6):848-54. doi: 10.1086/432803. Epub 2005 Aug 16.
4
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Diagn Microbiol Infect Dis. 2005 Jul;52(3):203-8. doi: 10.1016/j.diagmicrobio.2005.05.002.
5
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S354-67. doi: 10.1086/431676.
6
In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S315-32. doi: 10.1086/431673.
7
Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.
Arch Intern Med. 2005 Jun 27;165(12):1430-5. doi: 10.1001/archinte.165.12.1430.
8
Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection.
Antimicrob Agents Chemother. 2005 Jul;49(7):3018-20. doi: 10.1128/AAC.49.7.3018-3020.2005.
9
MRSA--what is it, and how do we deal with the problem?
Expert Opin Ther Targets. 2005 Apr;9(2):253-65. doi: 10.1517/14728222.9.2.253.
10
Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.
J Antimicrob Chemother. 2005 Jul;56(1):128-32. doi: 10.1093/jac/dki175. Epub 2005 May 25.
Zotero 插件